Paul Woodard has joined Immune-Onc Therapeutics as its chief medical officer. He comes to the Palo Alto, CA-based cancer immunotherapy developer from Bellicum Pharmaceuticals (NASDAQ: BLCM), where he was senior vice president of clinical and medical affairs. In other moves, Immune-Onc promoted An Song to chief scientific officer. Song was the company’s senior vice president of development sciences. Immune-Onc’s lead program is being developed as a potential treatment for acute myeloid leukemia and other cancers.